Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT01915498
Title Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Celgene
Age Groups: senior | adult
Covered Countries USA | FRA

Additional content available in CKB BOOST